PFM Health Sciences’s Boston Scientific BSX Stock Holding History

PFM Health Sciences’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-122,000	Closed	-$11.9M	–	82
2025 Q3	$11.9M	Buy	+122,000	New	+$12.6M	0.92%	36

Other funds holding BSX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

PFM Health Sciences's BSX Position: Q4 2025 in Review

PFM Health Sciences sold out of Boston Scientific (BSX) in Q4 2025, closing a stake of 28,648 shares — an estimated $2.8M sold.

PFM Health Sciences first reported a position in BSX in Q1 2018 and held it in 9 quarters. The position peaked at $73.4M in Q3 2018. 1,784 funds tracked by Wall St. Rank hold BSX as of Q4 2025.

PFM Health Sciences reported no remaining Boston Scientific position as of Q4 2025 after selling out during the quarter.
PFM Health Sciences sold 28,648 Boston Scientific shares in Q4 2025, an estimated $2.8M.
PFM Health Sciences first reported a position in Boston Scientific in Q1 2018 and held it in 9 quarters.
PFM Health Sciences's Boston Scientific position peaked at $73.4M in Q3 2018.
1,784 funds tracked by Wall St. Rank held Boston Scientific as of Q4 2025.

Based on PFM Health Sciences's 13F filing for Q4 2025, filed 17 Feb 2026.